A next-generation malaria vaccine has shown strong results in a Phase 3 trial, reducing severe disease by about 75% among young children in sub-Saharan Africa. The findings, reported by Reuters, add to hopes that a more effective vaccine could help blunt one of the world’s deadliest infectious diseases.

Malaria remains a major public health burden across much of the region, where children are especially vulnerable to life-threatening complications. Researchers say the late-stage data suggest the vaccine could become an important tool alongside bed nets, testing, treatment, and mosquito control programs.

The trial focused on severe illness prevention, a key measure for health systems that continue to face high childhood mortality from malaria. While additional review and rollout planning will be needed, the results represent a meaningful step forward for prevention efforts.

Health experts will now look closely at durability, access, and affordability, since any vaccine’s real-world impact will depend on how widely it can be delivered in communities most affected by the disease.